Novartis received SFDA approval to sell Lucentis (ranibizumab) in China. Lucentis is a treatment for wet (neovascular) age-related macular degeneration (AMD), which causes blindness and vision loss, usually in people over 50. The company also announced the China launch of Galvus (vildagliptin), an oral diabetes treatment. Galvus is a dipeptidyl peptidase IV (DPP-IV) inhibitor indicated for people with diabetes 2. More details....

Stock Symbol: (NYSE: NVS)

Share this with colleagues: